Journal of the American Society of Nephrology
2008 JASN IMPACT FACTOR 7.505 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on April 30, 2008
Journal of the American Society of Nephrology
© 2008 American Society of Nephrology
doi: 10.1681/ASN.2007080902
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
ASN.2007080902v1
19/8/1509    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mathew, S.
Right arrow Articles by Hruska, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mathew, S.
Right arrow Articles by Hruska, K. A.
Related Collections
Right arrowRelated Article

Received August 15, 2007
Accepted on March 24, 2008

BASIC RESEARCH

Vitamin D Receptor Activators Can Protect against Vascular Calcification

Suresh Mathew *, Richard J. Lund {dagger}, Lala R. Chaudhary *, Theresa Geurs *, and Keith A. Hruska *{ddagger}1

Renal Division, Departments of *Pediatrics and {ddagger}Medicine, Washington University School of Medicine, St. Louis, Missouri; and {dagger}Renal Division, Department of Medicine, Creighton University, Omaha, Nebraska


1 To whom correspondence should be addressed. E-mail: hruska_k{at}wustl.edu.


   Abstract

An apparent conflict exists between observational studies that suggest that vitamin D receptor (VDR) activators provide a survival advantage for patients with ESRD and other studies that suggest that they cause vascular calcification. In an effort to explain this discrepancy, we studied the effects of the VDR activators calcitriol and paricalcitol on aortic calcification in a mouse model of chronic kidney disease (CKD)-stimulated atherosclerotic cardiovascular mineralization. At dosages sufficient to correct secondary hyperparathyroidism, calcitriol and paricalcitol were protective against aortic calcification, but higher dosages stimulated aortic calcification. At protective dosages, the VDR activators reduced osteoblastic gene expression in the aorta, which is normally increased in CKD, perhaps explaining this inhibition of aortic calcification. Interpreting the results obtained using this model, however, is complicated by the adynamic bone disorder; both calcitriol and paricalcitol stimulated osteoblast surfaces and rates of bone formation. Therefore, the skeletal actions of the VDR activators may have contributed to their protection against aortic calcification. We conclude that low, clinically relevant dosages of calcitriol and paricalcitol may protect against CKD-stimulated vascular calcification.


Related Article

This Month's Highlights
J. Am. Soc. Nephrol. 2008 19: A6. [Full Text] [PDF]



This article has been cited by other articles:


Home page
J. Am. Soc. Nephrol.Home page
R. Thadhani
Is Calcitriol Life-Protective for Patients with Chronic Kidney Disease?
J. Am. Soc. Nephrol., November 1, 2009; 20(11): 2285 - 2290.
[Full Text] [PDF]


Home page
CJASNHome page
J. N. Artaza, R. Mehrotra, and K. C. Norris
Vitamin D and the Cardiovascular System
Clin. J. Am. Soc. Nephrol., September 1, 2009; 4(9): 1515 - 1522.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
I. H. de Boer, B. Kestenbaum, A. B. Shoben, E. D. Michos, M. J. Sarnak, and D. S. Siscovick
25-Hydroxyvitamin D Levels Inversely Associate with Risk for Developing Coronary Artery Calcification
J. Am. Soc. Nephrol., August 1, 2009; 20(8): 1805 - 1812.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
M. L. Melamed and R. Thadhani
Low Calcidiol Levels and Coronary Artery Calcification: True, True, and Related?
J. Am. Soc. Nephrol., August 1, 2009; 20(8): 1663 - 1665.
[Full Text] [PDF]


Home page
CJASNHome page
D. V. Barreto, F. C. Barreto, S. Liabeuf, M. Temmar, F. Boitte, G. Choukroun, A. Fournier, and Z. A. Massy
Vitamin D Affects Survival Independently of Vascular Calcification in Chronic Kidney Disease
Clin. J. Am. Soc. Nephrol., June 1, 2009; 4(6): 1128 - 1135.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
S. C. Palmer, J. C. Craig, and G. F. M. Strippoli
Taking aim at targets
Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1358 - 1361.
[Full Text] [PDF]


Home page
CJASNHome page
T. B. Drueke and E. Ritz
Treatment of Secondary Hyperparathyroidism in CKD Patients with Cinacalcet and/or Vitamin D Derivatives
Clin. J. Am. Soc. Nephrol., January 1, 2009; 4(1): 234 - 241.
[Abstract] [Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP